ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CRVS Corvus Pharmaceuticals Inc

1.80
0.01 (0.56%)
Last Updated: 15:57:39
Delayed by 15 minutes

Period:

Draw Mode:

Volume 270,161
Bid Price 1.78
Ask Price 1.80
News -
Day High 1.85

Low
0.607

52 Week Range

High
4.19

Day Low 1.762
Company Name Stock Ticker Symbol Market Type
Corvus Pharmaceuticals Inc CRVS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.56% 1.80 15:57:39
Open Price Low Price High Price Close Price Prev Close
1.79 1.762 1.85 1.79
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
714 270,161 $ 1.81 $ 487,696 - 0.607 - 4.19
Last Trade Time Type Quantity Stock Price Currency
15:58:26 1 $ 1.80 USD

Corvus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
88.27M 49.04M - 0 -41.31M -0.84 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Corvus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CRVS Message Board. Create One! See More Posts on CRVS Message Board See More Message Board Posts

Historical CRVS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.921.951.711.79267,806-0.12-6.25%
1 Month2.302.38991.711.98234,615-0.50-21.74%
3 Months1.922.581.712.11217,581-0.12-6.25%
6 Months1.472.581.051.80208,9810.3322.45%
1 Year0.64054.190.6072.22473,5471.16181.03%
3 Years3.059.540.6074.851,003,950-1.25-40.98%
5 Years4.009.540.6074.73839,872-2.20-55.00%

Corvus Pharmaceuticals Description

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Your Recent History

Delayed Upgrade Clock